SynthesisEFORT open reviews2026
Necrosis following neoadjuvant radiotherapy and its association with oncological outcome in soft tissue sarcoma patients: a systematic literature review and meta-analysis.
Synthesis in EFORT open reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Neoadjuvant radiotherapy (NRTX) is recommended for soft tissue sarcomas (STS) by current European Society of Medical Oncology (ESMO) guidelines. Histological response to preoperative treatment (including NRTX) is a well-established prognostic parameter in patients with osteosarcoma and Ewing sarcoma. In patients with STS, however, the relevance of histological - and radiological - necrosis rate following neoadjuvant treatment is less well known. Methods: We conducted a systematic PubMed search and obtained 2,433 potentially relevant entries, of which 30 original articles were finally included. Histological and radiological tumour necrosis following NRTX of STS was systematically studied, as was the potential association between the histological necrosis rate and oncological outcome (local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) and overall survival (OS)) using random-effects meta-analysis. Results: Information on 2,346 patients (1,257 males; 53.6%) of whom 2,228 (95.0%) had received NRTX was summarised. Most STS were located in the extremities (n = 2016; 85.9%). A histological necrosis rate of ≥90% was present in 22.8%. On imaging, the mean necrosis rate ranged between 14.7 and 67.7%. There was a significant association between higher histological necrosis rate and improved DMFS (HR = 0.29; 95% CI: 0.12-0.71; P = 0.018), while no associations for LRFS (HR = 0.54; 95% CI: 0.06-5.17; P = 0.181) or OS (HR = 0.60; 95% CI: 0.10-3.64; P = 0.437) were found. Conclusions: Tumour necrosis is frequently observed following NRTX in STS. Higher histological necrosis seems to be associated with improved DMFS. Overall, varying reporting of the histological and radiological necrosis rate following NRTX in STS calls for improved estimation of treatment response, considering histological and radiological features alike.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.